Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 511 - 520 of 764 studies

A Phase 1/2 Open-label, Dose-escalation, and Dose-expansion Study of mRNA-4194 in Participants with Lynch Syndrome (INTERCEPT-Lynch)

Cancer and neoplasms

M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Advanced or Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (AndroMETa-PDAC-288)

Cancer and neoplasms

BDTX-4933-101 - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Cancer and neoplasms

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Patients with Newly-Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-304)

Blood Cancer and neoplasms

Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Stroke

NeVa One Registry - Prospective, Open-Label, Multi-Center Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes (NeVa One)

A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG) (THYME)

Exploring the lived experience of patients with Congenital Myasthenic Syndromes (CMS) about assessment tools used clinically and patient view on what might capture meaningful change.

Respiratory

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF).